. Currently, the most rational target for a generic challenger is a highly profitable patent, whether it is weak or strong. The … settlement negotiations out of fear of the vagaries of patent trials. Given that blockbuster drugs are used to subsidize the …

other types of mechanisms in regulatory laws that provide patent-like protection or further strengthen existing patent … drug companies: data exclusivity and patent linkage. As noted in earlier chapters (separately posted on SSRN), not all … competition, a thorough understanding of these requirements (as well as how they intersect with patent protection) is important to …

first present descriptive results that chart the rise of brand-name patent portfolios and Paragraph IV challenges. Over time …, patenting has increased, measured by the number of patents per drug and the length of the nominal patent term. Meanwhile, the … fraction of drugs subjected to patent challenges has increased. Drugs are also challenged sooner, relative to brand …

development of new pharmaceuticals, particularly, of those that are needed in developing and underdeveloped countries. In addition … order to avoid strategic patent behavior, leading to a balance that guarantees the welfare and progress of developing …

A generic drug maker that has been sued for infringing a patent on a branded drug will sometimes promise, as part of an … agreement settling the litigation, to delay selling its drug until as late as the expiration of the patent term. I adapt the … standard optimal patent term model to determine whether the delay in competition caused by such agreements raises consumer …

Public-private partnerships offer a promising alternative paradigm for pharmaceutical innovation in complex disease … essential to accelerate pharmaceutical innovation. Patents threaten the potential of partnership strategies, however, by making … innovation is fundamentally flawed for two reasons. First, it ignores the competitive market pressures that both shape what is …

We argue that, in the pharmaceutical industry, excessive patent duration can deter investments in innovative treatments …

70 markets, the study finds that introduction of product patent for pharmaceuticals in the patent law has a positive …-income markets. Also, innovative pharmaceuticals are launched sooner than non-innovative ones, irrespective of the patent regime in …This paper examines access to new and innovative pharmaceuticals in a post-TRIPS era. The WTO’s TRIPS Agreement (TRIPS …

This working paper provides a statistical analysis of 74 patent families which cover subject matter relevant to ten …